O Mahari | seborrheic keratosis removal
Theraflax is a mixture of natural, cold pressed linseed oil, black cumin oil and borage oil. Serious side effects are not expected from these oils, but not every stomach can tolerate it. The mixture is supposed to soothe the immune system and the body to develop healthy skin tissue seborrheic keratosis removal. Especially people with psoriasis arthritis report longer lasting successes. There are numerous reports from people who Theraflax has helped in the long term. This does not mean that this oil therapy helps every psoriatist or works equally well with everyone. There are also reports of failures or only slight improvements.
The manufacturer points out that the oil mixture can normalize the growth of the skin cells. In the psoriasis arthritis, Theraflax is said to develop the healthy bones that surround the joint bone. The skin growth is controlled by essential fatty acids, which are contained in Theraflax. These essential fatty acids must be converted in the body of enzymes in order to become active. Such enzymes are present in the oils. Essential fatty acids and enzymes also produce hormone-like substances (prostaglandins), which influence inflammation in the body. If you want to know more details about how the manufacturer explains the way in which psoriasis works, please consult the manufacturer's website or the German importer.
Study in Sofia
Dr. med. Emil Iliev works at the Alexander University Hospital in the Department of Dermatology and Venereology in Sofia. On 1 July 2001, he carried out an investigation on behalf of the South African producer. Theraflax should be tested in patients with psoriasis vulgaris and psoriasis arthritis seborrheic dermatitis hair loss recovery. A brief interim report was presented in May 2002. The study itself is to be published at the end of 2002. Thereafter, 52 patients were treated with Theraflax and observed for at least six months. They received 10 ml of the oil mixture in the morning and in the evening.
In 22 patients, the psoriatic herd was significantly reduced. A further 18 patients were able to improve their symptoms. There were no improvements in 9 affected persons and the skin condition deteriorated in 3 persons. 19 subjects suffered from psoriasis arthritis. All had previously been treated in vain with methotrexate seborrheic dermatitis hair loss recovery. Almost all reported that between the 14th and the 28th day of treatment their pain disappeared and did not recur during the 6-month observation period. Only in a patient who had both skin and joint pso at the same time, no positive effect could be observed.
The therapy was discontinued by eleven patients - because their path was too long or for other personal reasons. A total of three patients completed the study prematurely because they received cholesterol problems. The laboratory values showed that Theraflax exerts a regulating effect on fat metabolism and, among other things, positive effect on cholesterol levels. There was no effect on liver data or urine values.